Gender and disease-inclusive nomenclature consolidation of theragnostic target, prostate-specific membrane antigen (PSMA) to folate hydrolase-1 (FOLH1)
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Ramirez-Fort, Marigdalia K.Gilman, Casey K.
Alexander, Jacob S.
Meier-Schiesser, Barbara
Gower, Arjan
Olyaie, Mojtaba
Vaidya, Neel
Vahidi, Kiarash
Li, Yuxin
Lange, Christopher S.
Fort, Migdalia
Deurdulian, Corinne
Keyword
General Medicinedisease-inclusive language
folate hydrolase-1
gender-inclusive language
prostate-specific membrane antigen
theragnostic target
Journal title
Frontiers in MedicineDate Published
2024-02-09Publication Volume
10
Metadata
Show full item recordCitation
Ramirez-Fort MK, Gilman CK, Alexander JS, Meier-Schiesser B, Gower A, Olyaie M, Vaidya N, Vahidi K, Li Y, Lange CS, Fort M, Deurdulian C. Gender and disease-inclusive nomenclature consolidation of theragnostic target, prostate-specific membrane antigen (PSMA) to folate hydrolase-1 (FOLH1). Front Med (Lausanne). 2024 Feb 9;10:1304718. doi: 10.3389/fmed.2023.1304718. PMID: 38444631; PMCID: PMC10913592.DOI
10.3389/fmed.2023.1304718ae974a485f413a2113503eed53cd6c53
10.3389/fmed.2023.1304718
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Related articles
- Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase.
- Authors: Bacich DJ, Pinto JT, Tong WP, Heston WD
- Issue date: 2001 Feb
- Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer.
- Authors: Noss KR, Wolfe SA, Grimes SR
- Issue date: 2002 Feb 20
- Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
- Authors: Schmittgen TD, Zakrajsek BA, Hill RE, Liu Q, Reeves JJ, Axford PD, Singer MJ, Reed MW
- Issue date: 2003 Jun 1
- (18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer.
- Authors: Mesci A, Ahmadi E, Ali A, Gouran-Savadkoohi M, Evelyn Tsakiridis E, Biziotis OD, Chow T, Kapoor A, Sur M, Steinberg GR, Liu S, Zukotynski K, Tsakiridis T
- Issue date: 2023 Mar
- Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
- Authors: Vornov JJ, Peters D, Nedelcovych M, Hollinger K, Rais R, Slusher BS
- Issue date: 2020 Jun